Skip to main content
TipRanks
Go Ultimate75% OFF

Renascience Inc. (4889) AI Stock Analysis

0 Followers
JP:4889

Renascience Inc.

(TSE/TYO:4889)

Select Model
Rating:44Neutral
Price Target:JPY 869.00â–¼(-3.01% Downside)
Action:reiterated
Date:11/06/26

Score primarily impacted by moderate financial performance amid revenue volatility and cash burn despite balance sheet gains, further pressured by weak technical momentum and unattractive valuation from negative earnings.

Positive Factors
Debt-free balance sheetEliminating debt materially reduces leverage and interest-related pressure, giving Renascience greater financial flexibility than in earlier periods. This stronger balance-sheet position can improve resilience and preserve options for investment or restructuring, even though operating performance remains weak.
Negative Factors
Declining revenueA sharp recent revenue decline signals weakening commercial momentum and reduces the scale over which fixed operating costs can be spread. Unless growth recovers, lower sales can prolong losses, constrain reinvestment, and make it harder for the company to convert its high gross margins into sustainable earnings.

Renascience Inc. (4889) vs. iShares MSCI Japan ETF (EWJ)

-60%-40%-20%0%20%40%JP:4889-51.17%EWJ+16.06%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
JPY 12.34B
Dividend Yield
―
Average Volume (3M)
259.93K
Price to Earnings (P/E)
-39.5
Beta (1Y)
1.13
Revenue Growth
-21.15%
EPS Growth
-931.83%
Country
Japan
Employees
3
Sector
General
Sector Strength
55
Industry
Medical - Pharmaceuticals

Renascience Inc. Business Overview & Revenue Model

Company Description

Renascience Inc., established in 2000 and based in Tokyo, Japan, is actively engaged in pioneering and bringing to market pharmaceuticals and medical devices throughout Japan. The company's pipeline includes RS5614, a PAI-1 inhibitor that has reached...

Renascience Inc. Financial Statement Overview

Summary

High revenue volatility with inconsistent growth, persistent operating and net losses, offset by a strengthening balance sheet through debt elimination and equity growth; ongoing cash burn highlights liquidity risks typical of biotech R&D.

Income Statement

35Negative

Balance Sheet

75Positive

Cash Flow

25Negative
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue68.55M68.55M132.69M194.16M100.55M139.33M
Gross Profit64.21M64.21M128.95M165.64M100.30M77.60M
EBITDA-335.12M-356.88M143.82M-250.50M-332.49M-244.65M
Net Income-316.44M-301.28M113.43M-258.33M-335.80M-254.29M
Balance Sheet
Total Assets3.29B3.50B1.87B2.09B2.27B2.44B
Cash, Cash Equivalents and Short-Term Investments3.20B3.40B1.80B2.03B2.21B2.39B
Total Debt000356.10M309.60M199.23M
Total Liabilities53.15M180.59M151.21M482.11M409.76M237.17M
Stockholders Equity3.24B3.32B1.72B1.61B1.87B2.20B
Cash Flow
Free Cash Flow0-291.31M-177.14M-232.10M-286.87M-231.66M
Operating Cash Flow0-291.31M-176.34M-230.52M-284.64M-230.49M
Investing Cash Flow00382.15M-1.57M232.00K-296.00K
Financing Cash Flow01.89B-52.18M46.50M110.37M1.59B

Renascience Inc. Technical Analysis

Technical Analysis SentimentNegative
Last Price896.00

Price Trends

50DMA1063.70Negative
100DMA1262.68Negative
200DMA1434.92Negative

Market Momentum

MACD-60.20Negative
RSI39.90Neutral
STOCH59.87Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4889, the sentiment is Negative. The current price of 896.00 is below the 20-day moving average (MA) of 945.15, below the 50-day MA of 1063.70, and below the 200-day MA of 1434.92, indicating a bearish trend. The MACD of -60.20 indicates Negative momentum. The RSI at 39.90 is Neutral, neither overbought nor oversold. The STOCH value of 59.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4889.

Renascience Inc. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

JP:4889 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
JP:4978JP:497844NeutralJPY 11.65B-25.06――-8.23%-48.10%
JP:4889JP:488944NeutralJPY 12.34B-39.45――-21.15%-931.83%
JP:7774JP:777442NeutralJPY 26.52B-73.78――17.05%10.47%
JP:4593JP:459339UnderperformJPY 30.90B-13.76――-51.55%52.19%
JP:4599JP:459938UnderperformJPY 7.33B-3.94―――4.85%
JP:7776JP:777637UnderperformJPY 6.70B-5.83――-49.43%-3.77%

* General Sector Average

Performance Comparison

-50%0%50%JP:4889JP:4593JP:4599JP:4978JP:7774JP:7776Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
JP:4889 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
JP:4889Renascience Inc.896.00-994.00-52.59%
JP:4593Healios KK228.00-223.00-49.45%
JP:4599StemRIM Inc.117.00-161.00-57.91%
JP:4978ReproCELL Inc.109.00-48.00-30.57%
JP:7774Japan Tissue Engineering Co., Ltd.653.00175.0036.61%
JP:7776CellSeed Inc.169.00-232.00-57.86%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 06, 2026